V2 sact_regimen
781,388 rows · 12 columns
| ENCORE_PATIENT_ID | MERGED_REGIMEN_ID | HEIGHT_AT_START_OF_REGIMEN | WEIGHT_AT_START_OF_REGIMEN | INTENT_OF_TREATMENT | DATE_DECISION_TO_TREAT | START_DATE_OF_REGIMEN | MAPPED_REGIMEN | CLINICAL_TRIAL | CHEMO_RADIATION | BENCHMARK_GROUP | LINK_NUMBER |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 20214665 | 20080914 | 1.8 | 81.3 | Neo-adjuvant (N) | null | 2018-05-18 | IMATINIB | 02 | N | IMATINIB | 100423812 |
| 20214666 | 20080915 | 1.62 | 0 | null | 2018-12-13 | 2018-12-23 | CAPECITABINE + CISPLATIN + Trastuzumab | 02 | null | CAPECITABINE + CISPLATIN + TRASTUZUMAB | 101811456 |
| 20214668 | 20080916 | 1.86 | 80 | Palliative (P) | 2019-05-19 | 2019-05-25 | Cape+Cisplatin+Trastuzumab Load | 02 | N | CAPECITABINE + CISPLATIN + TRASTUZUMAB | 101222197 |
| 20214669 | 20080917 | 1.7 | 57.5 | Palliative (P) | 2018-07-19 | 2018-07-30 | Trial Unspecified | 1 | N | TRIAL | 100293830 |
| 20214670 | 20080918 | null | null | null | 2018-11-03 | 2018-11-27 | CAPECITABINE + CISPLATIN + Trastuzumab | 02 | null | IMATINIB | 101009970 |
| 20214672 | 20080920 | 1.79 | 45.8 | Neo-adjuvant (N) | 2019-01-28 | 2019-02-26 | Trial Unspecified | Y | N | TRIAL | 101336542 |
| 20214673 | 20080921 | 1.67 | 87.9 | Curative (C) | 2017-12-23 | 2017-12-28 | FLUOROURACIL + MITOMYCIN + RT | N | N | FLUOROURACIL + MITOMYCIN + RT | 100388093 |
| 20214674 | 20080922 | 1.63 | 72.8 | Palliative (P) | 2019-11-07 | 2019-11-07 | Cape+Cisplatin+Trastuzumab Load | 02 | N | CAPECITABINE + CISPLATIN + TRASTUZUMAB | 100807305 |
| 20214675 | 20080923 | 1.65 | 83.9 | Palliative (P) | 2019-06-25 | 2019-07-14 | CAPECITABINE + CISPLATIN + Trastuzumab | 02 | N | IMATINIB | 100987455 |
| 20214677 | 20080925 | 1.75 | 58.8 | Palliative (P) | 2018-09-29 | 2018-10-14 | Trial Unspecified | Y | N | TRIAL | 100153133 |
| 20214678 | 20080926 | 1.6 | 103.3 | Curative (C) | 2018-01-28 | 2018-01-28 | Cape+Cisplatin+Trastuzumab Load | 02 | Y | FLUOROURACIL + MITOMYCIN + RT | 100712126 |
| 20214679 | 20080927 | 1.9 | 75.7 | Neo-adjuvant (N) | 2019-12-28 | 2019-12-29 | GO2 TRIAL | 01 | N | TRIAL | 101421218 |
| 20214680 | 20080928 | 1.76 | 81.5 | Palliative (P) | 2017-04-03 | 2017-04-25 | Cetuximab + FOLFIRI cycle 2 onwards | 02 | N | CETUXIMAB + FLUOROURACIL + IRINOTECAN | 101847067 |
| 20214681 | 20080929 | 1.7 | 52.8 | Neo-adjuvant (N) | 2019-09-09 | 2019-09-17 | HCX (Cape + Cisp + Tras) - Load | 02 | N | TRIAL | 101226955 |
| 20214684 | 20080931 | 1.61 | 54 | Palliative (P) | 2017-04-08 | 2017-04-22 | Cape+Cisplatin+Trastuzumab Main | 02 | N | CETUXIMAB + FLUOROURACIL + IRINOTECAN | 101868005 |
| 20214685 | 20080932 | 1.83 | 91.6 | Palliative (P) | 2019-11-17 | 2019-11-22 | HCX (Cape + Cisp + Tras) - Main | 02 | N | CETUXIMAB + FLUOROURACIL + IRINOTECAN | 100944557 |
| 20214686 | 20080933 | 1.63 | 89.6 | Palliative (P) | 2017-05-22 | 2017-05-25 | HCX (Cape + Cisp + Tras) - Load | 02 | N | FLUOROURACIL + MITOMYCIN + RT | 101730031 |
| 20214687 | 20080934 | 1.76 | 55.2 | Palliative (P) | 2018-09-25 | 2018-09-25 | Cape+Cisplatin+Trastuzumab Load | 02 | N | TRIAL | 100121366 |
| 20214688 | 20080935 | 1.8 | 61.8 | Curative (C) | 2018-08-16 | 2018-08-29 | FLUOROURACIL + MITOMYCIN + RT | N | Y | FLUOROURACIL + MITOMYCIN + RT | 100372480 |
| 20214689 | 20080936 | 1.71 | 116 | Palliative (P) | 2016-03-27 | 2016-03-27 | CAPECITABINE + CISPLATIN + Trastuzumab | 02 | N | CAPECITABINE + CISPLATIN + TRASTUZUMAB | 101705416 |
| 20214690 | 20080937 | null | 96 | null | 2019-12-03 | 2019-12-11 | LANREOTIDE | 02 | N | LANREOTIDE | 100997402 |
| 20214691 | 20080938 | 1.8 | 75.3 | Palliative (P) | 2018-08-06 | 2018-08-27 | HCX | 02 | N | CAPECITABINE + CISPLATIN + TRASTUZUMAB | 101706293 |
| 20214692 | 20080939 | 1.8 | 0 | Palliative (P) | 2020-01-25 | 2020-01-28 | HCX | 02 | N | CAPECITABINE + CISPLATIN + TRASTUZUMAB | 100944929 |
| 20214693 | 20080940 | 1.77 | 78 | null | 2017-07-21 | 2017-08-07 | IMATINIB | 02 | null | IMATINIB | 100858677 |
| 20214696 | 20080943 | 0 | 101 | Palliative (P) | 2020-11-10 | 2020-11-10 | LANREOTIDE | 02 | N | LANREOTIDE | 100405427 |
| 20214697 | 20080944 | null | null | Neo-adjuvant (N) | 2017-06-06 | 2017-06-08 | HCX (Cape + Cisp + Tras) - Main | 02 | N | IMATINIB | 101393969 |
| 20214698 | 20080945 | 1.69 | 75 | Curative (C) | 2017-05-08 | 2017-05-19 | Fluorouracil+Mitomycin+RT (Anal Ca) | N | Y | FLUOROURACIL + MITOMYCIN + RT | 101735652 |
| 20214699 | 20080946 | 1.81 | 73 | Curative (C) | 2018-10-20 | 2018-11-04 | Cape+Cisplatin+Trastuzumab Main | 02 | Y | FLUOROURACIL + MITOMYCIN + RT | 101334311 |
| 20214701 | 20080948 | 0 | 75.6 | Palliative (P) | 2018-10-16 | 2018-10-28 | Cape+Cisplatin+Trastuzumab Main | 02 | N | LANREOTIDE | 101411562 |
| 20214702 | 20080949 | 1.78 | 79.5 | Disease modification (D) | 2017-08-29 | 2017-09-05 | LANREOTIDE | 02 | N | LANREOTIDE | 100318140 |
| 20214704 | 20080950 | 1.62 | 0 | Neo-adjuvant (N) | 2017-03-12 | 2017-03-26 | Trial Unspecified | 01 | N | TRIAL | 101855992 |
| 20214705 | 20080951 | null | null | null | 2017-02-21 | 2017-02-21 | LANREOTIDE | 02 | null | LANREOTIDE | 100809606 |
| 20214707 | 20080952 | null | null | Palliative (P) | 2018-06-07 | 2018-06-07 | CAPECITABINE + CISPLATIN + Trastuzumab | 02 | N | LANREOTIDE | 100470515 |
| 20214708 | 20080953 | 1.78 | 90 | Curative (C) | 2017-07-11 | 2017-07-27 | FLUOROURACIL + MITOMYCIN + RT | N | Y | FLUOROURACIL + MITOMYCIN + RT | 101265338 |
| 20214709 | 20080954 | 1.7 | 113.8 | Palliative (P) | 2019-07-08 | 2019-07-08 | Trial Unspecified | Y | N | TRIAL | 100884035 |
| 20214710 | 20080955 | 1.7 | 104 | Curative (C) | 2017-08-21 | 2017-08-21 | Cape+Cisplatin+Trastuzumab Load | 02 | N | TRIAL | 100923969 |
| 20214711 | 20080956 | 1.66 | 59 | 03 | 2019-01-13 | 2019-01-20 | IMATINIB | 02 | N | IMATINIB | 101834093 |
| 20214712 | 20080957 | 1.64 | 0 | Curative (C) | 2018-04-09 | 2018-04-25 | FLUOROURACIL + MITOMYCIN + RT | N | Y | FLUOROURACIL + MITOMYCIN + RT | 100344610 |
| 20214715 | 20080958 | 0 | 73.9 | 03 | 2017-01-02 | 2017-01-02 | Imatinib 400mg | 02 | N | IMATINIB | 101446919 |
| 20214717 | 20080959 | 1.77 | 74.05 | Curative (C) | 2018-03-17 | 2018-04-12 | FLUOROURACIL + MITOMYCIN + RT | 02 | Y | FLUOROURACIL + MITOMYCIN + RT | 100161978 |
| 20214718 | 20080960 | 1.67 | 79.2 | Curative (C) | 2017-05-16 | 2017-06-08 | Fluorouracil+Mitomycin+RT (Anal Ca) | 02 | Y | FLUOROURACIL + MITOMYCIN + RT | 100390145 |
| 20214719 | 20080961 | 1.89 | 132 | Palliative (P) | null | 2016-11-08 | null | null | N | TRIAL | 100220145 |
| 20214722 | 20080962 | 1.82 | null | null | 2016-01-11 | 2016-02-12 | LANREOTIDE | 02 | null | LANREOTIDE | 100728345 |
| 20214723 | 20080963 | 1.9 | 81.6 | Palliative (P) | 2018-10-11 | 2018-10-18 | Trial Unspecified | 01 | N | TRIAL | 100412046 |
| 20214724 | 20080964 | 1.85 | 56.65 | Palliative (P) | 2019-08-03 | 2019-08-18 | TCX | 02 | N | CAPECITABINE + CISPLATIN + TRASTUZUMAB | 101661613 |
| 20214725 | 20080965 | 1.73 | 62.8 | Neo-adjuvant (N) | 2016-09-13 | 2016-09-22 | Cape+Cisplatin+Trastuzumab Load | 02 | N | CAPECITABINE + CISPLATIN + TRASTUZUMAB | 101509098 |
| 20214727 | 20080966 | 1.82 | 55.8 | null | 2019-07-12 | 2019-08-23 | CAPECITABINE + CISPLATIN + Trastuzumab | 02 | null | CETUXIMAB + FLUOROURACIL + IRINOTECAN | 101290093 |
| 20214728 | 20080967 | 1.6 | 73.3 | Curative (C) | 2016-11-12 | 2016-12-02 | FLUOROURACIL + MITOMYCIN + RT | 02 | Y | FLUOROURACIL + MITOMYCIN + RT | 100270613 |
| 20214729 | 20080968 | 1.68 | 78 | Palliative (P) | 2017-03-21 | 2017-04-03 | Cape+Cisplatin+Trastuzumab Load | 02 | N | CAPECITABINE + CISPLATIN + TRASTUZUMAB | 101011340 |
| 20214730 | 20080969 | 1.57 | 101 | Neo-adjuvant (N) | 2019-07-07 | 2019-07-07 | Trial Unspecified | 01 | N | TRIAL | 101383168 |